Clinical Trials Insight: 700028225
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2008
At a glance
- Drugs MRX 4 (Primary)
- Indications Allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Celsus Therapeutics
- 11 Jun 2008 Status changed to completed, according to a Morria Biopharmaceuticals media release.
- 16 Jan 2008 Interim safety results reported in a Morria Biopharmaceuticals media release.
- 06 Nov 2007 New trial record.